Immunologic Basis of Anti-IgE Therapy (Study II: On Patients With Asthma)

Completed · Phase 4 · Has a placebo group

Conditions studied: Asthma, Allergic Rhinitis, Atopic Dermatitis

In brief

The purpose of this study is to look at measures that will help scientists understand the way Omalizumab, an FDA-approved anti-allergy medication, works.

Key facts

Study ID

NCT00367016

Run by

University of California, Davis

People needed

6

Starts

2004-02-01

Expected to finish

2012-10-17

Last updated by the study team

2021-07-13

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Mild or moderate persistent asthma
• Allergic rhinitis
• Atopic dermatitis

You may not qualify if…

• Other lung diseases
• Blood clotting disorder
• Pregnant or lactating women

Where it is running

• UC Davis Department of Dermatology — Sacramento, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.